Request Deal Involvement

A consortium of investors led a $300m Series C funding round in Tessera Therapeutics.

Identify your role

Select the side you represented in this transaction, and provide your current job title.

Service Providers

Salutem

pr advisors

Salutem

Gibson Dunn & Crutcher

legal advisors

Gibson Dunn & Crutcher

White & Case

legal advisors

White & Case

or

Principals

TESSERA THERAPEUTICS

target

TESSERA THERAPEUTICS

ABU DHABI INVESTMENT AUTHORITY (ADIA)

bidder

ABU DHABI INVESTMENT AUTHORITY (ADIA)

ALASKA PERMANENT FUND CORPORATION

bidder

ALASKA PERMANENT FUND CORPORATION

ALTITUDE LIFE SCIENCE VENTURES

bidder

ALTITUDE LIFE SCIENCE VENTURES

ARTIS VENTURES

bidder

ARTIS VENTURES

CORMORANT ASSET MANAGEMENT

bidder

CORMORANT ASSET MANAGEMENT

FLAGSHIP PIONEERING

bidder

FLAGSHIP PIONEERING

HANWHA IMPACT PARTNERS

bidder

HANWHA IMPACT PARTNERS

LONGEVITY VISION FUND

bidder

LONGEVITY VISION FUND

MARCH CAPITAL PARTNERS

bidder

MARCH CAPITAL PARTNERS

SALT FUND

bidder

SALT FUND

SOFTBANK VISION FUND 2

bidder

SOFTBANK VISION FUND 2

T. ROWE PRICE GROUP INC

bidder

T. ROWE PRICE GROUP INC

QATAR INVESTMENT AUTHORITY

bidder

QATAR INVESTMENT AUTHORITY

Principals or Service Provider not listed?Add missing Service Provider or Principal

Enter your Job Title on this deal

This title will appear on your profile next to this deal involvement.


To help us verify your involvement, please include links to any relevant publications that mention you or your company's role in this deal:

All rights reserved. Copyright © 2025 Datasite

MergerLinks - Request Credit - A consortium of investors led a $300m Series C funding round in Tessera Therapeutics.